Ireland - English Select A Country Media Room

NEW APPROACHES, NEW IDEAS

By investing in research and fostering a passionate environment devoted to innovation, we’re able to discover and create products that address patients’ most pressing health needs. Our portfolio of leading medicines, together with deep expertise across key areas of health and a robust pipeline of promising compounds, helps us make a difference for patients around the world.

Partnerships Play a Key Role

We also know that some of the most important medical breakthroughs often result from collaborative R&D agreements and from partnerships. To find potential new therapies for patients we look both inside and outside AbbVie for promising discoveries. We partner and collaborate with peer companies, universities, non-governmental organisations, as well as other relevant groups, to help find solutions for patients around the globe—because we recognise there are times when we can accomplish more together than alone.
 


ABBVIE JOINS LANDMARK 15-YEAR IRISH GENOMIC RESEARCH ALLIANCE

genomics-lg

In early 2017, AbbVie announced a research partnership with Genomics Medicine Ireland (GMI) and WuXi NextCODE to undertake a landmark population genomics alliance in Ireland.

The 15-year project aims to sequence the genomes of 45,000 participants to identify novel targets and advance the clinical development of better treatments for a range of serious diseases. The collaboration will focus on key AbbVie therapeutic areas including oncology, neuroscience and immunology that affect hundreds of thousands of people in Ireland and hundreds of millions worldwide.


ABBVIE IN IRELAND – OUR COMMITMENT TO RESEARCH

SFI_logo_2016


AbbVie is committed to research in Ireland. In 2015, a joint investment of €10 million by the Department of Jobs, Enterprise, and Innovation through Science Foundation Ireland (SFI) in a partnership with AbbVie was announced involving two new therapeutic research partnerships in Ireland.

The collaborations, which will each investigate disease markers and potential targets against which new drugs could be developed, involve serious illnesses such as Crohn’s disease, rheumatoid arthritis, psoriasis and multiple sclerosis. Researchers at the SFI APC Microbiome Institute in University College Cork (UCC) and at the Trinity Biomedical Sciences Institute in Trinity College Dublin are involved.



Our Passion Helps Patients

Innovation is the cornerstone of AbbVie’s business as a global biopharmaceutical company. Our focus is on developing medicines that can offer strong clinical performance and provide measurable patient benefit —particularly in areas where there is significant need—such as virology, neuroscience, immunology, oncology and general medicine.

AbbVie’s approach to scientific innovation builds on an impressive track record of developing breakthrough science. Our scientists discovered and developed two of the first medications to treat HIV infection, helping to change the outlook for many patients impacted by this disease. Our work in immunology has benefited patients with rheumatoid arthritis, psoriasis, Crohn’s disease and other chronic, autoimmune conditions. We continue to advance scientific research across many disease areas.

focusimg2_03

FOCUS AREAS

Our core therapeutic areas include Hepatitis C (HCV), neuroscience, immunology, oncology, renal disease and women’s health.

Learn more »

focusimg_02

PIPELINE

We’re committed to advancing promising compounds and research to deliver essential therapies to patients.

View pipeline »

focusimg_03

RESEARCH & DEVELOPMENT

Our efforts are focused on areas where we believe we can have an even greater impact on the disease and how it is managed.

See our process »

Leave abbvie.ie

The AbbVie Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which the site is directed, please contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The AbbVie Internet site that you have requested may be in a language that differs from your country of origin.

The AbbVie Internet site that you have requested may not be optimised for your screen size.

Do you wish to continue to this AbbVie site?

Exit abbvie.ie

Notice

The “Yes” link below will take you out of AbbVie family of websites.

Links which take you out of AbbVie worldwide web sites are not under the control of AbbVie, and AbbVie are not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?